FDA Accepts 510(k) Application for 23andMe Health Report on Bloom Syndrome | GenomeWeb

NEW YORK (GenomeWeb) –The US Food and Drug Administration has accepted for review 23andMe's 510(k) application for a single-condition health report, the consumer genomics firm informed customers.

"Although the submission focuses on a single rare but serious inherited condition we report to customers — Bloom syndrome — it is an important step in our work with the FDA in the coming months," Kathy Hibbs, 23andMe's chief legal and regulatory officer, wrote in a blog post.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.